ArticleJournal of thoracic disease2026
Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selection bias and molecular blind spots: re-evaluating flumonertinib rechallenge in third-generation TKI-resistant non-small cell lung cancer.Journal of thoracic disease · 2026Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Third-generation tyrosine kinase inhibitor (TKI) agents have become the preferred option for the first-line treatment of patients with epidermal growth factor receptor ( Methods: This retrospective study included a cohort of 40 patients who received flumonertinib after prior third-generation EGFR-TKI therapy following resistance to other third-generation TKIs. Kaplan-Meier analysis, Cox proportional hazards regression analysis, and Cox subgroup analysis were employed to examine factors influencing patient survival. Results: The median progression-free survival (PFS) for the overall cohort was 8.95 months, and the median overall survival (OS) was 18.03 months. Patients who received flumonertinib after prior third-generation EGFR-TKI therapy (80 or 160 mg) as first- to third-line therapy (≤3 prior lines of therapy) demonstrated significantly improved survival outcomes [hazard ratio (HR) =0.43, 95% confidence interval (CI): 0.20-0.89; P=0.02]. Cox subgroup analysis further revealed that patients receiving flumonertinib monotherapy derived a significant survival benefit (HR =0.24, 95% CI: 0.07-0.85, P=0.02; P for interaction =0.04). Conclusions: For patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.